Boehringer Targets High Unmet Need With Spesolimab Filing
Could Be First EU Approved Drug For Generalized Pustular Psoriasis Flares
Executive Summary
Boehringer Ingelheim files spesolimab in the EU, where it is a forerunner in the race to fill the unmet need in generalized pustular psoriasis flares.
You may also be interested in...
Boehringer’s Spesolimab Wins First Approval In Rare Skin Condition
The German firm’s monoclonal antibody has received a US thumbs-up for a severe skin disease with high unmet need but it must address diagnostic and educational hurdles.
AnaptysBio’s Imsidolimab Meets Yet Another Failure
The company is discontinuing the drug’s development in hidradenitis suppurativa after a Phase II flop, leaving GPP as the only viable indication, for which it is planning to out-license the drug.
Beware The Ides of March? AnaptysBio's Imsidolimab Has Another Trial Failure
After the 14 March announcement that the IL-36R agonist failed in an acne study, it appears to have better chances in generalized pustular psoriasis, an underserved orphan indication where the target is already validated.